Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Baranda, Antonio Jimeno
Cancer vaccines strive to induce robust, antigen-targeted, T-cell-mediated immune responses but have struggled to produce meaningful regression in solid tumors. An autologous cell vaccine, SQZ-PBMC-HPV, was developed by SQZ Biotechnologies using microfluidic squeezing technology to load PBMCs with HPV16 E6 and E7 antigens in HLA-A*02+ patients. The SQZ-PBMC-HPV-101 Phase 1 trial (NCT04084951) enrolled patients with incurable HPV16+ cancers. Here, we present a post hoc analysis of the relationship between Posttreatment CD8+ T cell infiltration and patient outcomes...
May 2, 2024: Molecular Carcinogenesis